Y-mAbs Therapeutics
Gérard Ber is the current director at Y-mAbs Therapeutics. Gérard has also served as a non executive board member at Progenics Pharmaceuticals, Inc. from November 2019 to June 2020. Prior to that, they were the COO Group/co founder at AAA from January 2002 to January 2018.
From September 2000 to April 2002, they were the Export Area Manager Western Europe at OM Pharma Switzerland. Gérard then became a consultant for Novartis following the acquisition of Advanced Accelerator Application from January 2018 to January 2019. Prior to that, they served as a board member at IEL UK from January 2014 to January 2018.
From January 1994 to December 2000, they were the Directeur filiale at CIS bio international - Groupe ORIS.
Gérard Ber attended IPI Paris for their schooling. Gérard then went on to get their DESS in Bromatologie from the faculté de Pharmacie-Grenoble. Finally, they completed their Doctorat en Pharmacie from the Faculté de Pharmacie -Grenoble.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Y-mAbs Therapeutics
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.